Bacitracin/Neomycin/Polymyxin-B 400u/3.5mg/10,000u/gm Ointment Y41.8 Bacitracin/Polymyxin-B 500u/10,000u/gm Ointment Y41.8 ...

Global strategies to contain the spread of AMR include a coordinated surveillance network and the development of novel classes of anti-infectives. In June 2021, the WHO released its fourth Global ...

In Anti-infectives research (AIR) group, we work to contribute to solutions for tackling global health challenges in access to anti-infective medication and antimicrobial resistance. Our research ...

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US, UK ...

A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer ...

Last year, GSK said it was planning to invest a cool £1 billion in infectious diseases, with an emphasis on neglected tropical diseases and antimicrobial resistance (AMR). Now, its spent some of ...

Program enables access to R327G for diabetic foot infections (DFI), following recent positive Phase II results in acute bacterial skin and skin-structure infections (ABSSSI), including diabetic foot ...

"Among the top therapies, anti-infectives and respiratory have shown a relatively stronger volume growth for the month of June," said Sheetal Sapale, VP, commercial at Pharmarack. Industry data ...

covering its new class of synthetic anti-infectives. The patent, which extends to 2041, marks the fourth granted under this family, alongside approvals in Australia, Canada, and Israel ...